CRO’s revamped site provides a portal to dynamic content encouraging visitors to interact, contribute and learn about improving the efficiency of clinical trials
(Durham, NC: June 23, 2009) Health Decisions (www.healthdec.com, DIA Booth 1447), a full-service clinical research organization (CRO) specializing in high-efficiency adaptive solutions, announces the launch of its new website at www.healthdec.com. The website is designed to let visitors engage in conversations about improving clinical trial efficiency while experiencing the company’s Agile Clinical Development platform. These connections are made through interactive tools and dynamic content, including a blog, audio and video content, articles, and white papers featuring a variety of viewpoints on ways to increase efficiency both from the Health Decisions team and third-party experts. Visitors are encouraged to join the conversation by submitting comments, asking questions on the FAQs page, and contacting the company with suggestions.
"We are excited to use this forum to share and discuss the concept of Agile Clinical Development. These principles have always defined how we work, and it is important to give our sponsors and other members of the drug development community an opportunity to weigh in," said Ryan Hedspeth, director of marketing for Health Decisions. "We hope this website will grow into a valuable resource for information on industry trends and for learning about the latest clinical trial processes and technologies."
The website also lets visitors easily access important background information on the company’s history, leadership team, services and therapeutic expertise, and includes information for job seekers, investigators, and media. Head to www.healthdec.com to see the new site, or click on one of the links below to go directly to a video or blog post that interests you.
Videos Subscribe
Site Management - Health Decisions"Site Management" - Mike Ford, director of data management, discusses ways to improve the performance of investigator sites.
Transparency and Control - Health Decisions"Transparency and Control" - CEO Michael Rosenberg discusses how providing the right information to the right eyes at the right time helps sponsors take control of their trials and make better decisions.
From the Blog Subscribe
"Web EDC is still coming up short for sponsors" - Lori Hill, manager of IT internal development points out the industry’s frustrations with current Web EDC systems, and suggests ways to move toward improvement.
See Us at DIA, Booth 1447
Stop by the Health Decisions exhibit, where the company will be demoing its SmartPen advanced EDC tool and asking attendees the question, “Are You Agile?” View the show press release.
Also, make sure to follow @healthdecisions on Twitter at for early access to breaking news from DIA and information on how to get in touch with adaptive research experts on the show floor.
About Health Decisions
Health Decisions (www.healthdec.com), a global clinical research organization (CRO), leads the industry in trial efficiency. Through integrated technology and agile clinical development methods that apply adaptive principles to both trial design and operations, Health Decisions provides sponsors unprecedented transparency and control and produces results 10 - 40% faster than traditional approaches.
Health Decisions is headquartered in Durham, NC, with over twenty years of drug development experience in setting new standards of speed and accuracy for pharmaceutical, biotech and medical drug and device companies in Phase I-IV trials across all major therapy areas. For more information, please visit the company’s website at www.healthdec.com.
SOUL Trial Shows Oral Semaglutide Significantly Reduces Cardiovascular Risk in Type 2 Diabetes
April 3rd 2025Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease, with benefits consistent with injectable semaglutide and other GLP-1 receptor agonists.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.